Han et al. [56] reported that dioscin can lower blood UA levels and may successfully treat hyperuricaemia by suppressing pro-inflammatory cytokine production, blocking the TLR4/NF-κB signaling pathway, and inhibiting NLRP3 activation. Here, NFKB1 is linked to hyperuricemia.